Actavis has launched Irinotecan, a cancer drug, in the UK, France, the Netherlands, Germany, Austria and Sweden on 13 and 14 July. The patents expired on 12 and 13 July, respectively.
Irinotecan Hydrochloride concentrate for solution for infusion is the generic equivalent to Pfizer’s Camptosar, and is available in 40mg/2ml and 100mg/5ml vials. Irinotecan is used in the treatment of patients with metastatic carcinoma of the colon.
Actavis and Medis, have launched Irinotecan in more than 20 countries. Irinotecan Actavis is a product of Actavis Romania. Actavis entered the market for hospital products with the acquisition of Sindan in Romania in 2006. The company’s focus in this field is on oncology products, with a growing range of anti-infectives, local anaesthetics and analgesics.